NSHSFNanoSphere Health Sciences Inc.
The schedule
- Thu15Oct
Given mounting payables and virtually zero liquidity, NSHSF must secure immediate financing or initiate debt restructuring to maintain operations and SEC/OTC filing status.
- Tue15Dec
- Wed20Jan
Auditor review and OTC regulatory scrutiny regarding NSHSF's viability as a going concern, given extreme capital deficiency and prolonged sub-penny trading.
- Thu15Apr
With core operations stalled, NSHSF's remaining intrinsic value lies strictly in its status as a clean public shell for a reverse merger transaction.
- Tue15Jun
The Q3 2026 earnings release will serve as a definitive marker of whether NanoSphere has secured any commercial biotech partnerships or remains an entirely dormant entity.
- Tue14Sep
Past
- Tue15Sep
NSHSF's next quarterly financial report is critical for going-concern viability given the extreme $1.8K cash balance and zero trailing revenue. With the stock technically overbought (RSI 82.8) on a micro-cap base, risk is heavily skewed to the downside.